Healthcare - Asia Tech Wire

Healthcare

16:12

                            Lilly's weight loss drug sold on Chinese e-commerce platforms
                        
                            A number of e-commerce platforms in China have already provided treatment pickup services for Eli Lilly's glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide (trade name: Mounjaro).
                        
15:21

                            UK to trial AI tool to assess diabetes risk
                        
                            Britain will launch a trial next year of an artificial intelligence (AI) tool that can predict the risk of type 2 diabetes 13 years before a patient develops the disease, The Guardian reported Monday.
                        
14:58

                            WuXi AppTec divests part of cell therapy business to counter potential U.S. restrictions
                        
                            Chinese pharmaceutical company WuXi AppTec (603259.SH; 2359.HK) is divesting part of its cell therapy business in a bid to deal with potential U.S. restrictions.
                        
21:30

                            WuXi AppTec: WuXi ATU business transaction is expected to be completed in the first half of 2025
                        
                            WuXi AppTec announced that its indirect wholly-owned subsidiaries WuXi ATU Holding Limited and WuXi ATU Limited signed an Equity Purchase Agreement with Altaris LLC on December 24, 2024, transferring all of their equity in WuXi Advanced Therapies Inc. and Oxford Genetics Limited to Altaris in cash. This transaction does not constitute a major transaction, does not involve related-party transactions, and does not constitute a major asset reorganization. From January to November 2024, the total operating income of Advanced Therapies and Oxford Genetics was approximately RMB 980 million, accounting for 2.4% of the company's audited operating income in the most recent fiscal year. This transaction must be completed in accordance with the provisions of the Equity Purchase Agreement and is expected to be completed in the first half of 2025.
                        
10:40

                            Judge Katharine Parker, who is overseeing the pre-trial hearings for Luigi Mangione, is married to a former Pfizer, $PFE, executive and holds hundreds of thousands of dollars in stock, including in healthcare companies & pharmaceutical companies
                        
22:33

                            Novo Nordisk rebounded by more than 4%
                        
                            Novo Nordisk rebounded more than 4%, as analysts said the company's weight loss drugs are still the most effective.
                        
17:44

                            Merck to invest more than $72.88 million in new advanced materials development center in Japan
                        
                            German pharmaceutical giant Merck announced last week that it will invest more than 70 million euros ($72.88 million) to build a new advanced materials development center at its Shizuoka plant in Japan.
                        
16:08

                            Novo Nordisk's European shares rose 6.2%, on track for their best performance since August.
                        
16:04

                            Novo Nordisk shares opened up 6% in Europe
                        
                            Novo Nordisk's European shares opened 6% higher.
                        
05:37

                            Eli Lilly's weight-loss drug Zepbound approved for sleep apnea
                        
                            Eli Lilly's weight loss drug Zepbound has been approved to treat sleep apnea.
                        
22:33

                            Eli Lilly (LLY.N) rose more than 4% as rival Novo Nordisk's weight loss drug trial results fell short of expectations.
                        
19:33

                            Novo Nordisk spokesperson: The Cagrisema trial allowed for dose reduction; even though only 57% of Cagrisema patients reached the highest dose, statistically significant results were achieved.
                        
19:32

                            Novo Nordisk spokesperson: Regulatory filing for Cagrisema is expected by the end of 2025. We are encouraged by the properties of Cagrisema, which appears safe, well tolerated, and broadly similar to other GLP-1s.
                        
19:32

                            Novo Nordisk spokesperson: We plan to optimize dose adjustments and further explore Cagrisem's potential for additional weight loss, with plans to start a new trial in the first half of 2025.
                        
19:31

                            Novo Nordisk spokesperson: The complete Cagrisema results will be announced at a medical congress next year.
                        
1735114365
101785
3

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Trends

electric vehicle China Tesla Chinese Company South Korea AI Apple Samsung India Huawei

Weekly Highlights

                                    Taiwan's weighted index rose 2.6%, with semiconductor stocks leading the gains, and TSMC rising more than 4%
                            2024-12-23

                                    Tuanmaimai, the WeChat community group buying business under Meituan (03690.HK), issued an announcement stating that due to platform business adjustments, Tuanmaimai will cease operations from 24:00 on December 31, 2024.
                            2024-12-23

                                    MediaTek releases AI chip Dimensity 8400, equipped with Dimensity AI intelligent engine
                            2024-12-23

                                    Japanese regulators intend to order Google to rectify its actions for suspected monopoly, the company responded
                            2024-12-23

                                    Xiaomi Motors officially integrates VLM visual language model
                            2024-12-23